# Summary of Consolidated Financial Results for FY2020

May 13, 2021 Mitsui Chemicals, Inc.

(Unit : Billions of Yen)

(Unit : Billions of Yen)

#### 1. Summary of Operating Results

	FY2019	FY2020	Incr. (Decr.)		Outlook fo	or FY2021
		(Decr.)			Interim	Full year
Sales revenue	1,349.5	1,211.7	(137.8)	Γ	670.0	1,400.0
Operating income before special items	72.3	85.1	12.8		60.0	115.0
Operating income	64.6	78.1	13.5		57.0	113.0
Net income	42.6	64.2	21.6		45.5	88.0
Net income attributable to owners of the parent	34.0	57.9	23.9		41.5	79.0

# 2. Sales Revenue and Operating Income before Special Items by Business Segment

·Sales revenue

	FY2019 FY20	EY2020	FY2020 Incr. (Decr.)	Break	down	Outlook fo	or FY2021
		1 1 2020		Volume	Price	Interim	Full year
Mobility	367.9	315.5	(52.4)	(43.1)	(9.3)	185.0	385.0
Health Care	143.2	143.9	0.7	0.2	0.5	73.0	150.0
Food & Packaging	201.3	197.7	(3.6)	5.3	(8.9)	100.0	215.0
Basic Materials	619.5	541.4	(78.1)	(4.2)	(73.9)	305.0	635.0
Others	17.6	13.2	(4.4)	-	(4.4)	7.0	15.0
Total	1,349.5	1,211.7	(137.8)	(41.8)	(96.0)	670.0	1,400.0

· Operating income before special items

(Unit : Billions of Yen) Breakdown Outlook for FY2021 Incr. FY2019 FY2020 Fixed (Decr.) Volume Price\* Costs Interim Full year etc. 20.5 44.0 Mobility 43.1 30.2 (12.9) (12.6) 0.0 (0.3) 9.5 21.0 Health Care 13.2 19.9 0.5 6.7 0.3 5.9 10.5 24.0 22.0 Food & Packaging 17.0 5.0 2.3 2.0 0.7 36.0 24.0 Basic Materials 9.4 19.6 10.2 (4.1) 17.5 (3.2) (0.5) (1.0) Others (2.9) (1.1) 1.8 1.8 \_ -(4.0) (9.0) (5.5) Adjustment (7.5)2.0 2.0 --Total 85.1 12.8 19.8 6.9 60.0 115.0 72.3 (13.9)

\*Price includes both selling and purchasing price variances.

3. Summary of Statement of Financial Position

	Assets				
	As of Mar. 31, 2020	As of Mar. 31, 2021	Incr. (Decr.)		
Current assets	781.8	787.6	5.8		
Property, plant and equipment & right-of-use assets	499.7	502.0	2.3		
Goodwill and intangible assets	26.2	20.8	(5.4)		
Other non-current assets	222.8	247.7	24.9		
Total assets	1,530.5	1,558.1	27.6		
[ Inventories ]	284.3	258.8	(25.5)		

(Unit : Billions of Yen)					
	Lia	bilities and Eq	uity		
	As of Mar. 31, 2020	Incr. (Decr.)			
Interest-bearing liabilities	599.4	563.8	(35.6)		
Other liabilities	321.4	312.2	(9.2)		
Equity attributable to owners of the parent	529.2	607.9	78.7		
Non-controlling interests	80.5	74.2	(6.3)		
Total liabilities and equity	1,530.5	1,558.1	27.6		
[ Net D/E Ratio ]	0.81	0.60	(0.21)		

# 4. Summary of Statement of Cash Flows

	FY2019	FY2020	Incr. (Decr.)
Cash flows from operating activities	142.2	174.3	32.1
Cash flows from investing activities	(109.1)	(77.5)	31.6
Free cash flows	33.1	96.8	63.7
Cash flows from financing activities	(6.4)	(69.0)	(62.6)
Others	(1.6)	3.6	5.2
Net incr.(decr.) in cash and cash equivalents	25.1	31.4	6.3
Cash and cash equivalents at the end of period	164.6	196.0	31.4

(Unit : Billions of Yen)					
Outlook for FY2021					
Interim	Full year				
68.0	123.0				
(64.0)	(134.0)				
4.0	(11.0)				
16.0	(10.0)				
0.0	0.0				
20.0	(21.0)				

#### 5. Accounting Fundamentals

		FY2020
R & D expenses	¥Billions	33.8
Depreciation & amortization	¥Billions	76.6
Capital expenditures	¥Billions	93.2
Financing incomes & expenses	¥Billions	(3.2)
Interest-bearing liabilities	¥Billions	563.8
Net D/E Ratio	percentage	0.60
Number of employees	person	18,051
Exchange rate	Yen / US\$	106
Domestic standard naphtha price	Yen / KL	31,300

#### 6. Scope of Consolidation and Equity Method

	As of Mar. 31,	As of Mar. 31,	Incr. (Decr.)	Outlook fo	or FY2021
	2020	2021		Interim	Full year
Consolidated subsidiaries	125	123	(2)	125	125
Joint operations	4	4	-	4	4
Non-consolidated subsidiaries and affiliates	27	27	0	26	26
Total	156	154	(2)	155	155

#### 7. Dividends

	Annual Dividends per Share (yen)						
	1st Q	Interim (2nd Q)	3rd Q	Year-end (4th Q)	Annual		
FY2020 Result	-	50.00	-	50.00	100.00		
FY2021 Forecast	-	55.00	-	55.00	110.00		

# 8. Number of Shares Outstanding (common stock)

	FY2019	FY2020
Number of shares outstanding at term-end (including treasury stock)	204,580,115	204,608,615
Number of shares of treasury stock at term-end	13,557,163	8,664,390
Average number of shares	194,648,574	194,202,034

Outlook for FY2021			
Interim	Full year		
20.0	39.0		
40.0	83.0		
71.0	140.0		
(2.5)	(5.0)		
590.0	575.0		
0.58	0.61		
18,300	18,300		
108	108		
48,000	48,000		

# 1. **Operating Results**

# (1) Overview

In the fiscal period under review (the twelve-month period from Apr 1, 2020 to March 31, 2021, hereinafter the "fiscal 2020"), the global economy remained extremely harsh due to various restrictions imposed to stem the spread of coronavirus. Although the economy has shown signs of recovery after restrictions were lifted, some countries and regions have repeatedly imposed restrictions due to continued outbreaks.

In Japan as well, manufacturing sector has shown signs of recovery but the outlook remains uncertain as the government has made several emergency declarations due to continued outbreaks.

On the other hand in the domestic chemical industry, the situation was temporary harsh because of the pandemic but utilization of naphtha crackers is headed toward a recovery as the economy begins to recover.

Under these circumstances, the Mitsui Chemicals Group (hereafter "the Group") worked for business expansion and growth in three business domains—Mobility, Health Care, and Food & Packaging—while also creating and developing Next Generation Business and further enhancing competitiveness in the area of Basic Materials.

In Mobility, there has been diversified needs for lighter, more comfortable vehicles in the automotive industry in addition to a shift toward electric cars and needs for improved fuel economy. Regarding polypropylene compounds, which is contributing for lighter vehicles, our first production base in Europe began commercial operations. In addition, aiming to seize growing demand in Asia, we expanded the production facilities of our base in Thailand. As for our gear oil additive LUCANT<sup>™</sup>, which helps improve the fuel economy and longevity of automobiles, we completed construction of a new plant in Ichihara Works to meet expanding global demand. And regarding APEL<sup>™</sup>, which is mainly used in smartphone camera lenses in the information communication technology (ICT) industry, we began construction of a new plant in Osaka Works to meet a rapid increase in demand.

In Health Care, in addition to declining birthrates and aging populations in advanced countries and growing economies in emerging markets, health consciousness is rising due in part to current measures to address the pandemic. In non-woven fabric, to meet the robust demand for masks and medical staff support in light of the pandemic, our subsidiary Sunrex Industry Co., Ltd. established a production system for non-woven fabric for medical gowns and expanded production facilities for TEKNOROTE<sup>™</sup> mask nose clamps. Regarding our ophthalmic lens materials boasting the world-leading market share, we expanded our product lineup by purchasing COTEC GmbH to manufacture, market, and research water-repellent and anti-refractive coating materials. In addition, as for dental materials, we concluded a capital business alliance agreement with SHOFU INC., which is a manufacturer of dental materials and equipment, with the aim of enhancing corporate value and raising our presence in the market.

In Food & Packaging, food security is becoming a major social issue amid global population growth and climate change. With standards of living in Asia rising, the packaging field is seeing growing needs for more highly functional products with a smaller environmental footprint. In performance films and sheets, we decided to expand production facilities for ICROS<sup>™</sup> Tape, which commands the largest share of the global market for protective tape used in semiconductor manufacturing processes. In agrochemicals, the Group acquired registration in Japan for its insecticide BROFREYA<sup>™</sup> SC, which utilizes the new agent TENEBENAL<sup>™</sup> as the active ingredient. Pesticide-resistant pests have become a major problem in crop production and we will continue to help combat the issue.

In Basic Materials, which is centered on petrochemicals and basic chemicals, the Group provides materials to various manufacturing fields, including automobiles, residences,

consumer electronics, infrastructure and packaging. As a strategic foundation, we have moved forward to enhance, expand, optimize and reconstruct downstream products in order to strengthen competitiveness. We strove to further rationalize our crackers, such as by reducing and stabilizing costs through raw material diversification and improving energy efficiency through the installation of a new gas turbine. In order to enhance downstream products, the Group has resolved Honshu Chemical Industry Co., Ltd., which possesses high level of technology in the area of performance polymers relating to ICT, Mobility and Health Care, to become a subsidiary through a tender offer.

Moreover, the Group continues to minimize negative impact on profit and loss by shrinking inventory and reducing fixed costs. The status of other responses is as follows.

1. Measures taken to ensure the health and safety of customers and employees from the perspective of maintaining functions for preventing the spread of infection and continuing business

Mitsui Chemicals, Inc. (hereafter "the Company") has been recommending teleworking and minimizing number of employees working at the workplace. For operations that are necessary to maintain business functions and can only be done at the workplace, the Company is taking such measures as staggering work times, ensuring thorough handwashing, and requiring masks to be worn.

2. Operational status of main business locations (suspension of operations at plants, impact on sales and production activities, and outlook on reopenings at the time of disclosure) At present, there has been no impact to the production at the Company's main manufacturing facilities located at each business location.

3. Production and supply status of major products (inventory levels, procurement of raw materials, securement of alternative methods, and outlook)

Each segment has been impacted by a decrease in sales, but the Company is working collaboratively and sharing information with customers as well as thoroughly and properly managing inventory by flexibly adjusting production based on the latest demand forecasts. At present, there has been no major disruption in the procurement of raw materials for major products.

4. Customer trends (trends in orders, and outlook)

In the automotive field, some of the major customers for our main products appear to have scaled back production. The Company will continue to carefully monitor the situation to minimize the impact.

The Company will continue to respond to coronavirus from the perspectives of business continuity and social contribution.

The Group reported the following operating results for fiscal 2020, which have been prepared in accordance with International Financial Reporting Standards (IFRS). The Group has applied operating income before special items as a management indicator, which is operating income excluding non-recurring items.

				(Billions of Yen)
	Sales Revenue	Operating Income before Special Items	Operating Income	Net Income Attributable to Owners of the Parent
Fiscal 2020	1,211.7	85.1	78.1	57.9
Previous fiscal year	1,349.5	72.3	64.6	34.0
Difference	(137.8)	12.8	13.5	23.9
Ratio (%)	(10.2)	17.7	20.9	70.4

**Sales revenue** decreased 137.8 billion yen, or 10.2%, compared with the previous fiscal year to 1,211.7 billion yen. This was mainly attributable to decrease in sales prices due to the fall in naphtha and other raw materials and fuel prices, in addition to decrease in sales resulting from the spread of coronavirus.

**Operating income before special items** was 85.1 billion yen, an increase of 12.8 billion yen or 17.7% year on year. This result was due to favorable terms of trade and reduction of fixed costs, despite of decrease in sales resulting from the spread of coronavirus.

**Operating income** was 78.1 billion yen, increased 13.5 billion yen or 20.9% year on year. This result was mainly due to increase of operating income before special items.

**Financial income/expenses** worsened 0.1 billion yen year on year to 3.9 billion yen loss, due to a decline of dividend income received.

As a result of the aforementioned factors, **income before income taxes** amounted to 74.2 billion yen, an increase of 13.4 billion yen or 22.1% year on year.

**Net income attributable to owners of the parent** after accounting for income taxes and non-controlling interests was 57.9 billion yen, an increase of 23.9 billion yen or 70.4% compared with the previous fiscal year. Basic earnings per share for the period were 298.00 yen.

# (2) Results by Business Segment

The status of each segment during fiscal 2020 is as follows.

#### Mobility

Sales revenue decreased 52.4 billion yen compared with the previous fiscal year to 315.5 billion yen and comprised 26% of total sales. Operating income before special items decreased 12.9 billion yen to 30.2 billion yen year on year. The decrease in income was due to slowing demand for automobile.

In elastomers, performance compounds, overseas polypropylene compound, and solution business, sales decreased due to the impact of coronavirus.

In **performance polymers**, the Group captured demand and sales remained healthy for ICT-related products.

#### Health Care

Sales revenue increased 0.7 billion yen year on year to 143.9 billion yen and comprised 12% of total sales. Operating income before special items increased 6.7 billion yen to 19.9 billion yen, mainly due to healthy sales in nonwoven fabrics.

In vision care materials, sales of ophthalmic lens materials stayed firm.

In **nonwoven fabrics**, sales of masks, medical gowns and disposable diapers stayed healthy.

In **dental materials**, sales decreased due to the impact of coronavirus.

# Food & Packaging

Sales revenue decreased 3.6 billion yen compared with the previous fiscal year to 197.7 billion yen and comprised 16% of total sales. On the other hand, operating income before special items increased 5.0 billion yen to 22.0 billion yen year on year, due to healthy sales in agrochemicals and industrial films and sheets.

In coatings & engineering materials, sales decreased due to the impact of coronavirus.

In performance films and sheets, sales were firm mainly in industrial films and sheets.

In agrochemicals, overseas sales were healthy.

#### **Basic Materials**

Sales revenue decreased 78.1 billion yen compared with the previous fiscal year to 541.4 billion yen and accounted for 45% of total sales. On the other hand, operating income before special items increased 10.2 billion yen to 19.6 billion yen, due to improved overseas market.

**Naphtha cracker** operating rates were lower than the previous fiscal year due to decreased demand of downstream products, which was impacted by coronavirus. Performances of **polypropylene** was affected by slowing demand for automotive products.

For Bisphenol A and Acetone, overseas market was at higher level than the previous fiscal year.

# Others

Sales revenue decreased 4.4 billion yen to 13.2 billion yen, comprised 1% of total sales. On the other hand, operating income before special items was 1.1 billion yen loss, increase of 1.8 billion yen compared to the previous year.

# 2. Financial Position

# (1) Status of Assets, Liabilities and Net Assets

**Total assets** at the end of fiscal year stood at 1,558.1 billion yen, an increase of 27.6 billion yen compared with the end of the previous fiscal year.

**Total liabilities** at the end of fiscal year decreased 44.8 billion yen compared with the previous fiscal year-end to 876.0 billion yen. **Interest-bearing debt** amounted to 563.8 billion yen, a decrease of 35.6 billion yen compared with the previous fiscal year-end. As a result, the interest-bearing debt ratio was 36.2%, a decrease of 3.0 percentage point.

**Total equity** was 682.1 billion yen, an increase of 72.4 billion yen compared with the previous fiscal year-end. The **ratio of equity attributable to owners of the parent** was 39.0%, an increase of 4.4 percentage point.

Accounting for the aforementioned factors, the **net debt-equity ratio** stood at 0.60 at the end of the fiscal year, 0.21 point decrease from the previous fiscal year-end.

# (2) Cash Flow Status

Cash and cash equivalents (hereafter called "net cash") at the end of the fiscal year increased 31.4 billion yen to 196.0 billion yen compared with the previous fiscal year-end.

#### **Cash Flows from Operating Activities**

Net cash provided by operating activities increased 32.1 billion yen to 174.3 billion yen due to increase of income before income taxes and decrease of income taxes paid.

#### **Cash Flows from Investing Activities**

Net cash used in investing activities decreased 31.6 billion yen compared with the previous fiscal year to 77.5 billion yen, mainly due to decrease of cash outflows from capital expenditure.

#### **Cash Flows from Financing Activities**

Net cash used in financing activities increased 62.6 billion yen compared with the previous fiscal year to 69.0 billion yen due primarily to increase of repayments of interest-bearing debt.

	FY2016 (As of March 31, 2017)	FY2017 (As of March 31, 2018)	FY2018 (As of March 31, 2019)	FY2019 (As of March 31, 2020)	FY2020 (As of March 31, 2021)				
Shareholders' Equity Ratio (%)	33.9	35.7	36.8	34.6	39.0				
Shareholders' Equity Ratio on a Market Value Basis (%)	41.5	46.6	34.7	25.6	44.0				
Ratio of Interest-bearing Debt to Cash Flows	4.4	5.6	4.4	4.2	3.2				
Interest Coverage Ratio (Times)	17.3	14.8	19.9	25.5	37.1				

# (3) Trends in Cash Flow Indicators

Notes:

- Shareholders' Equity Ratio: Shareholders' equity to total assets.

- Shareholders' Equity Ratio on a Market Value Basis: Market capitalization to total assets.

- Ratio of Interest-bearing Debt to Cash Flows: Interest-bearing debt to cash flows.

- Interest Coverage Ratio: Cash flows to interest paid.

- Each of the indicators was calculated using consolidated financial figures.

- The market capitalization was calculated by multiplying the closing share price as of the end of the period with the number of shares outstanding (excluding treasury stock).

- Operating cash flow figures have been used for cash flow calculations.

- Interest-bearing debt is the portion of total debt booked on the consolidated balance sheet on which interest is being paid. Interest paid is the amount of interest paid as reported in the consolidated statements of cash flows.

- Figures before FY2018 are based on Japanese GAAP.

# 3. Outlook for Fiscal 2021 (Year Ending March 31, 2022)

# (1) Overall of Financial Outlook for Fiscal 2021

In fiscal 2021, the global economy is expected to continue to be impacted by the global spread of the coronavirus. Although signs of economic recovery are expected to remain steady due to economic measures and wide availability of vaccines, concerns of another outbreak of infections persist.

In Japan, the manufacturing sector of the domestic economy is expected to remain on track toward recovery thanks to signs of a global economic recovery. However, there are worries that activities could be restricted due to the spread of coronavirus.

In the chemical industry, although demand is expected to expand due to signs of economic recovery, chemical companies should remain vigilant regarding fluctuations of raw materials

and other chemical product markets.

Under these conditions, the Group forecasts its business performance and earnings growth for fiscal 2021 as follows.

					(Billions of Ye
	Sales Revenue	Operating Income before Special Items	Operating Income	Net Income	Net Income Attributable to Owners of the Parent
Fiscal 2021	1,400.0	115.0	113.0	88.0	79.0
Fiscal 2020	1,211.7	85.1	78.1	64.2	57.9
Difference	188.3	29.9	34.9	23.8	21.1
Ratio (%)	15.5	35.1	44.7	37.0	36.5

Outlook above are based on the following assumptions:

a) Exchange rate for the full year is 108 yen/US\$

b) Average price of domestic naphtha is 48,000 yen /kl

c) "Operating income before special items" is operating income excluding non-recurring items (losses resulting from withdrawing from and downsizing businesses, etc.).

# (2) Outlook by FY2021 Business Segment

Outlook by FY2021 business segment is as follows.

(Billions of	Yen)
--------------	------

	Sales Revenue								
	Mobility	Health Care	Food & Packaging	Basic Materials	Others	Adjustment	Total		
Fiscal 2021	385.0	150.0	215.0	635.0	15.0	-	1,400.0		
Fiscal 2020	315.5	143.9	197.7	541.4	13.2	-	1,211.7		
Difference	69.5	6.1	17.3	93.6	1.8	-	188.3		
Ratio (%)	22.0	4.2	8.8	17.3	13.4	-	15.5		

(Billions of Yen)

	Operating Income before Special Items								
	Mobility	Health Care	Food & Packaging	Basic Materials	Others	Adjustment	Total		
Fiscal 2021	44.0	21.0	24.0	36.0	(1.0)	(9.0)	115.0		
Fiscal 2020	30.2	19.9	22.0	19.6	(1.1)	(5.5)	85.1		
Difference	13.8	1.1	2.0	16.4	0.1	(3.5)	29.9		
Ratio (%)	45.8	5.8	9.1	83.3	-	-	35.1		

# 4. Basic Policy on Appropriation of Profits, Cash Dividends for Fiscal 2020 and 2021 (Year Ending March 31, 2021 and March 31, 2022) (1) Basic Policy on Appropriation of Profits

In addition to continually raising dividends in line with performance trends, the Company will flexibly acquire treasury stock depending on the stock price and market environment, therefore to enhance returns to shareholders.

Specifically, the Company will aim to achieve a total return ratio of 30% or more.

Note: Total return ratio = (dividends paid + treasury stock acquired) / net income attributable to owners of the parent

From the fiscal year ending March 31, 2022, the Company will enhance stable and continual dividends over the medium to long term, and flexibly acquire treasury stock to provide appropriate returns to shareholders.

Specifically, the Company will aim to realize a steady 3% or higher for dividends on equity (DOE) and a total return ratio of 30% or more.

Note: Dividends on equity = dividends paid / total equity attributable to owners of the parent

# (2) Cash Dividends for Fiscal 2020 and 2021

Considering the recent business conditions, the Company plans to pay a year-end dividend of 50 yen per share in current fiscal year.

Because a 50 yen interim dividend was already paid out on December 2, 2020, dividends for the full fiscal year will total 100 yen per share and total return ratio will be 33.9%.

Turning to dividends for the fiscal year ending March 31, 2022, the Company plans to pay an interim dividend of 55 yen and a year-end dividend of 55 yen, totaling 110 yen per share for the full year.

# 5. Concept for Selection of Accounting Standard

Based on the Group's development of global business activities, the Group voluntarily adopted IFRS from the first quarter of fiscal 2020 for the purpose of improving international comparability of financial information in capital market and enhance its business management by unifying accounting standard across the Group.

#### Millions of yen **Transition Date** FY2019 FY2020 As of As of As of April 1, 2019 March 31, 2020 March 31, 2021 Assets Current assets Cash and cash equivalents 139,489 164,571 195,987 Trade receivables 285,846 313,953 273,894 299,621 284,306 258,814 Inventories Other financial assets 34,174 36,805 27,176 Other current assets 16,718 22,258 15,230 Total 803,955 781,834 783,053 Assets held for sale 4,519 Total current assets 803,955 781,834 787,572 Non-current assets Property, plant and equipment 437,991 453,188 455,749 Right-of-use assets 48,823 46,462 46,211 Goodwill 1,483 1,476 1,123 Intangible assets 24,390 19,678 24,759 22,406 23,222 Investment property 23,250 Investments accounted for using equity method 87.623 87.620 97.509 57,463 Other financial assets 108,536 62,882 Retirement benefit assets 40,459 33,939 55,059 Deferred tax assets 8,450 9,097 9,333 6,786 6,008 5,206 Other non-current assets Total non-current assets 786,947 748,681 770,553 Total assets 1,590,902 1,530,515 1,558,125

# 6. Consolidated Statements of Financial Position

		Millions of yen			
	Transition Date As of April 1, 2019	FY2019 As of March 31, 2020	FY2020 As of March 31, 2021		
Liabilities and equity					
Liabilities					
Current liabilities					
Trade payables	155,947	121,011	119,712		
Bonds and borrowings	191,575	232,793	216,721		
Income taxes payable	7,510	4,518	6,195		
Other financial liabilities	108,879	90,007	84,242		
Provisions	1,176	1,828	1,157		
Other current liabilities	34,264	35,517	37,736		
Total	499,351	485,674	465,763		
Liabilities directly associated with assets held for sale	-	-	542		
Total current liabilities	499,351	485,674	466,305		
Non-current liabilities					
Bonds and borrowings	322,749	313,237	293,495		
Other financial liabilities	60,862	69,003	67,722		
Retirement benefit liabilities	55,662	25,146	16,384		
Provisions	4,291	4,294	3,698		
Deferred tax liabilities	16,286	23,017	27,834		
Other non-current liabilities	638	437	530		
Total non-current liabilities	460,488	435,134	409,663		
Total liabilities	959,839	920,808	875,968		
Equity					
Share capital	125,205	125,298	125,331		
Capital surplus	79,256	79,320	74,009		
Treasury stock	(29,869)	(39,254)	( , , ,		
Retained earnings	350,695	359,794	424,084		
Other components of equity	26,495	4,062	9,397		
Total equity attributable to owners of the parent	551,782	529,220	607,921		
Non-controlling interests	79,281	80,487	74,236		
Total equity	631,063	609,707	682,157		
Total liabilities and equity	1,590,902	1,530,515	1,558,125		

# 7. Consolidated Statements of Income Statements and Consolidated Statements of Comprehensive Income Statements

Sales revenue         Cost of sales         Gross profit         Selling, general and administrative expenses         Other operating income         Other operating expenses         Share of profit of investments accounted for using equity method         Operating income         Financial income         Financial expenses         Income before income taxes         Income tax expense         Net income         Owners of parent         Non-controlling interests	April 1, 2019 to March 31, 2020 (1,051,139) 298,383 (226,592) 8,823 (20,557) 4,512 64,569 5,406 (9,151) 60,824 (18,205) 42,619	April 1, 2020 to March 31, 2021 (917,883 293,842 (211,980 (211,980 (14,183 5,989 78,074 4,297 (8,128 74,243 (10,024
Cost of sales         Gross profit         Selling, general and administrative expenses         Other operating income         Other operating expenses         Share of profit of investments accounted for using equity method         Operating income         Financial income         Financial expenses         Income before income taxes         Income tax expense         Net income         Vet income attributable to:         Owners of parent         Non-controlling interests	(1,051,139) 298,383 (226,592) 8,823 (20,557) 4,512 64,569 5,406 (9,151) 60,824 (18,205)	(917,883 293,842 (211,980 4,406 (14,183 5,989 78,074 4,297 (8,128 74,243
Gross profit Selling, general and administrative expenses Other operating income Other operating expenses Share of profit of investments accounted for using equity method Operating income Financial income Financial expenses Income before income taxes Income tax expense Net income Net income attributable to: Owners of parent Non-controlling interests	298,383 (226,592) 8,823 (20,557) 4,512 64,569 5,406 (9,151) 60,824 (18,205)	293,842 (211,980 4,406 (14,183 5,989 78,074 4,297 (8,128 74,243
Selling, general and administrative expenses Other operating income Other operating expenses Share of profit of investments accounted for using equity method <b>Operating income</b> Financial income Financial expenses Income before income taxes Income tax expense Net income Net income attributable to: Owners of parent Non-controlling interests	(226,592) 8,823 (20,557) 4,512 <b>64,569</b> 5,406 (9,151) <b>60,824</b> (18,205)	(211,980 4,406 (14,183 5,989 <b>78,074</b> 4,297 (8,128 <b>74,243</b>
Other operating income Other operating expenses Share of profit of investments accounted for using equity method Operating income Financial income Financial expenses Income before income taxes Income tax expense Net income Net income attributable to: Owners of parent Non-controlling interests	8,823 (20,557) 4,512 <b>64,569</b> 5,406 (9,151) <b>60,824</b> (18,205)	4,406 (14,183 5,989 <b>78,074</b> 4,297 (8,128 <b>74,243</b>
Other operating expenses Share of profit of investments accounted for using equity method Operating income Financial income Financial expenses Income before income taxes Income tax expense Net income Net income attributable to: Owners of parent Non-controlling interests	(20,557) 4,512 64,569 5,406 (9,151) 60,824 (18,205)	(14,183 5,989 <b>78,074</b> 4,297 (8,128 <b>74,243</b>
Share of profit of investments accounted for using equity method Operating income Financial income Financial expenses Income before income taxes Income tax expense Net income Net income attributable to: Owners of parent Non-controlling interests	4,512 64,569 5,406 (9,151) 60,824 (18,205)	5,989 78,074 4,297 (8,128 74,243
Operating income Financial income Financial expenses Income before income taxes Income tax expense Net income Net income attributable to: Owners of parent Non-controlling interests	64,569 5,406 (9,151) 60,824 (18,205)	<b>78,074</b> 4,297 (8,128 <b>74,243</b>
Financial income Financial expenses Income before income taxes Income tax expense Net income Net income attributable to: Owners of parent Non-controlling interests	5,406 (9,151) <b>60,824</b> (18,205)	4,297 (8,128 <b>74,243</b>
Financial expenses Income before income taxes Income tax expense Net income Net income attributable to: Owners of parent Non-controlling interests	(9,151) 60,824 (18,205)	(8,128 <b>74,243</b>
Income before income taxes Income tax expense Net income Net income attributable to: Owners of parent Non-controlling interests	60,824 (18,205)	74,243
Income tax expense Net income Net income attributable to: Owners of parent Non-controlling interests	(18,205)	
Net income Net income attributable to: Owners of parent Non-controlling interests		
Net income attributable to: Owners of parent Non-controlling interests		64,219
Non-controlling interests		• 1,2 10
Non-controlling interests	33,970	57,873
•	8,649	6,346
Net income	42,619	64,219
Earnings per share		
Basic earnings per share (Yen)	174.52	298.00
Consolidated Statements of Comprehensive Income)		
	Millions	of yen
	FY2019 April 1, 2019 to March 31, 2020	FY2020 April 1, 2020 to March 31, 2021
Net income	42,619	64,219
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Financial assets measured at fair value through other comprehensive income	(15,162)	670
Remeasurements of defined benefit plans	(6,834)	24,60
Share of other comprehensive income of investments accounted for using equity method	36	263
Total of items that will not be reclassified to profit or loss	(21,960)	25,538
Items that may be reclassified to profit or loss		
	(5,582)	5,816
Exchange differences on translation of foreign operations	788	579
Exchange differences on translation of foreign operations Effective portion of net change in fair value of cash flow hedges		(00)
	(1,834)	(280
Effective portion of net change in fair value of cash flow hedges Share of other comprehensive income of investments accounted for	(1,834)	
Effective portion of net change in fair value of cash flow hedges Share of other comprehensive income of investments accounted for using equity method		6,11
Effective portion of net change in fair value of cash flow hedges Share of other comprehensive income of investments accounted for using equity method Total of items that may be reclassified to profit or loss	(6,628)	(280 6,115 <b>31,65</b> 3 <b>95,872</b>
Effective portion of net change in fair value of cash flow hedges Share of other comprehensive income of investments accounted for using equity method Total of items that may be reclassified to profit or loss <b>Total other comprehensive income, net of tax</b>	(6,628) (28,588)	6,115 <b>31,65</b> 3
Effective portion of net change in fair value of cash flow hedges Share of other comprehensive income of investments accounted for using equity method Total of items that may be reclassified to profit or loss <b>Total other comprehensive income, net of tax</b> <b>Comprehensive income</b>	(6,628) (28,588)	6,115 <b>31,65</b> 3

14,031

95,872

Comprehensive income

# 8. Consolidated Statements of Cash Flows

	Millions	s of yen
	FY2019	FY2020
	April 1, 2019 to March 31, 2020	April 1, 2020 to March 31, 2021
Net cash provided by (used in) operating activities		
Income before income taxes	60,824	74,243
Depreciation and amortization	76,009	76,621
Impairment loss	6,389	8,050
Insurance income	(5,174)	(1,761)
Interest and dividend income	(4,827)	(2,152)
Interest expenses	5,542	4,634
Share of loss (profit) of investments accounted for using equity method	(4,512)	(5,989)
Decrease (increase) in trade receivables	35,027	(7,113)
Decrease (increase) in inventories	12,673	27,360
Increase (decrease) in trade payables	(31,551)	(5,420)
Other	2,405	10,312
Subtotal	152,805	178,785
Interest and dividends received	9,054	6,246
Proceeds from insurance income	5,174	1,761
Interest paid	(5,589)	(4,705)
Income taxes paid	(19,212)	(7,764)
Net cash provided by (used in) operating activities	142,232	174,323
Net cash provided by (used in) investing activities		
Purchase of marketable securities	(5,000)	-
Proceeds from sale and redemption of marketable securities	1	5,000
Purchase of property, plant and equipment	(95,116)	(74,904)
Proceeds from sale of property, plant and equipment	1,140	591
Purchase of intangible assets	(4,655)	(1,677)
Proceeds from sale of intangible assets	376	84
Purchase of investment securities	(1,230)	(877)
Proceeds from sale and redemption of investment securities	357	161
Purchase of subsidiaries	-	(1,722)
Purchase of equity accounted investments	-	(4,460)
Proceeds from equity accounted investments	_	99
Other	(4,985)	150
Net cash provided by (used in) investing activities	(109,112)	(77,555)

	Millions	of yen
	FY2019	FY2020
	April 1, 2019 to March 31, 2020	April 1, 2020 to March 31, 2021
Net cash provided by (used in) financing activities		
Increase (decrease) in short-term borrowings	(647)	(8,498)
Increase(decrease) in commercial papers	50,000	(10,000)
Proceeds from long-term borrowings	26,327	19,542
Repayments of long-term borrowings	(58,759)	(42,963)
Proceeds from issuance of bonds	20,000	15,000
Redemption of bonds	(426)	(10,426)
Repayments of lease liabilities	(7,282)	(8,108)
Proceeds from sale of treasury stock	20	3
Purchase of treasury stock	(9,389)	(691)
Dividends paid	(19,509)	(19,349)
Dividends paid to non-controlling interests	(6,700)	(6,266)
Proceeds from sale of interests in subsidiaries to non-controlling interests	_	2,800
Net cash provided by (used in) financing activities	(6,365)	(68,956)
Effect of exchange rate change on cash and cash equivalents	(1,673)	3,604
Net increase (decrease) in cash and cash equivalents	25,082	31,416
Cash and cash equivalents at beginning of period	139,489	164,571
Cash and cash equivalents at end of period	164,571	195,987

#### 9. Segment Information

#### (1) Overview of Reportable Segments

The Group's business segments are components of the Group for which separate financial information is available and that are regularly reviewed by the Board of Directors (chief operating decision maker) to make decisions about management resources to be allocated to the segments and assess their performance.

The Group positions business sector distinguished by their products and services within its headquarters. Each business sector proposes comprehensive domestic and overseas strategies in addition to pursuing business expansion in its respective product and service area.

Comprehensively considering similarities such as the details of products and services and target markets, the four reportable segments (distinguished by products and services) that comprise the Group's operations without aggregating the business segments are: Mobility, Health Care, Food & Packaging, and Basic Materials. Business segments, which are not included in the reportable segments, are classified into "Others."

#### Major products manufactured and sold by business segments are as follows:

Se	gments	Major Products and Businesses
Reportable Segments	Mobility	Elastomers, performance compounds, functional polymers, polypropylene compounds and comprehensive services regarding to the development of automotive and industrial products (Solution business)
	Health Care	Vision care materials, nonwoven fabrics, dental materials and, personal care materials
	Food & Packaging	Coating & engineering materials, performance films and sheets and, agrochemical products
	Basic Materials	Ethylene, propylene, polyethylene, polypropylene, catalysts, phenols, PTA, PET, polyurethane materials and, industrial chemical products
Others	Others	Other related businesses, etc.

#### (2) Methods to Determine Sales Revenue, Income or Loss, Assets, and Others by Reportable Business Segment Income by reportable business segment is stated on a basis of operating income before special items, which is operating income excluding non-recurring items (losses resulting from withdrawing from and downsizing businesses, etc.). Intersegment transaction pricing and transfer pricing are negotiated and determined based on prevailing market prices.

#### (3) Information concerning Sales Revenue, Income or Loss, Assets, and Others by Reportable Business Segment

Transition Date (As of April 1, 2019)							(Mill	ions of yen)	)	
		Reportable Segment				Others		Adjustment		
	Mobility	Health	Food &	Basic	Total	(Note 1)	Sum total	Sum total '	(Note 2)	Consolidated
	woonity	Care	Packaging	Materials	Total			(		
Segment assets	363,340	199,451	245,895	655,876	1,464,562	73,531	1,538,093	52,809	1,590,902	
Other items										
Investments accounted for using equity method	22,419	2,748	2,313	57,585	85,065	2,558	87,623		87,623	

Notes: 1. "Others" encompasses business segments not included in the reportable segments and includes other related businesses, etc.

2. The 52,809 million in adjustments to segment assets includes corporate assets of 213,842 million not allocated to reportable segments and negative 161,033 million elimination of intersegment transactions. Corporate assets are mainly attributed to the Company's surplus management funds (cash and deposits), long-term investment funds (investment securities), deferred tax assets and administrative departments.

The previous fiscal year (April 1, 2019 – March 31, 2020)					(Millions of yen)				
		Rej	oortable Segm	nent		Others		Adjustment	
	Mobility	Health Care	Food & Packaging	Basic Materials	Total	(Note 1)	Sum total	(Note 2)	Consolidated
Sales revenue									
1) To external customers	367,910	143,147	201,309	619,520	1,331,886	17,636	1,349,522	-	1,349,522
2) Intersegment	11,446	3,183	1,708	66,681	83,018	59,894	142,912	(142,912)	
Total	379,356	146,330	203,017	686,201	1,414,904	77,530	1,492,434	(142,912)	1,349,522
Segment income (Operating income before special items)	43,104	13,233	17,003	9,396	82,736	(2,981)	79,755	(7,425)	72,330
Segment assets	367,094	195,956	242,414	597,162	1,402,626	66,993	1,469,619	60,896	1,530,515
Other items Depreciation and amortization Share of profit of investments accounted for using equity method	17,919 2,808	11,865 242	9,705 72	30,476 564	69,965 3,686	5,311 —	75,276 3,686	733 826	76,009 4,512
Impairment loss	670	5,137	222	210	6,239	-	6,239	150	6,389
Investments accounted for using equity method	21,884	4,270	1,081	56,180	83,415	4,205	87,620	-	87,620
Capital expenditures (Note 3)	33,501	11,271	16,586	38,247	99,605	6,433	106,038	501	106,539

Notes: 1. "Others" encompasses business segments not included in the reportable segments and includes other related businesses, etc.

2. The negative 7,425 million in adjustments to segment income includes corporate expenses of negative 7,975 million not allocated to reportable segments and 550 million elimination of intersegment transactions. Corporate expenses mainly comprise general & administrative expenses which are usually not attributed to segments and R&D expenses for new business. The 60,896 million in adjustments to segment assets includes corporate assets of 197,416 million not allocated to reportable segments and a negative 136,520 million elimination of intersegment transactions. Corporate assets are mainly attributed to the Company's surplus management funds (cash and deposits), long-term investment funds (investment securities), deferred tax assets and administrative departments. 3. Capital expenditure includes property, plant and equipment, intangible assets and investment property etc.

-	Reportable Segment					0.1			
	Mobility	Health Care	Food & Packaging	Basic Materials	Total	Others (Note 1)	Sum total	Adjustment (Note 2)	Consolidated
Sales revenue	0.15.100		107 700	= 4 4 9 9 9		10.000			
1) To external customers	315,480	143,933	197,700	541,382	1,198,495	13,230	1,211,725	(110.070)	1,211,725
2) Intersegment Total	9,104 324,584	2,496 146,429	2,224 199,924	54,061 595,443	67,885 1,266,380	51,785 65,015	119,670 1,331,395	(119,670)	1,211,725
Segment income	524,504	140,423	133,324	555,445	1,200,300	00,010	1,001,000	(113,070)	1,211,725
(Operating income before special items)	30,177	19,852	21,989	19,642	91,660	(1,045)	90,615	(5,475)	85,140
Segment assets	346,837	199,251	253,218	606,146	1,405,452	80,790	1,486,242	71,883	1,558,125
Other items									
Depreciation and amortization	17,463	10,991	10,419	32,245	71,118	4,862	75,980	641	76,621
Share of profit of investments accounted for using equity method	1,999	(175)	272	3,482	5,578	-	5,578	411	5,989
Impairment loss	5,486	153	182	2,112	7,933	-	7,933	117	8,050
Investments accounted for using equity method	20,845	11,349	1,987	60,535	94,716	2,793	97,509	_	97,509
Capital expenditures (Note 3)	21,136	9,582	13,485	39,376	83,579	9,156	92,735	435	93,170

Notes: 1. "Others" encompasses business segments not included in the reportable segments and includes other related businesses, etc.

The negative 5,475 million in adjustments to segment income includes corporate expenses of negative 5,506 million not allocated to reportable segments and 31 million elimination of intersegment transactions. Corporate expenses mainly comprise general & administrative expenses which are usually not attributed to segments and R&D expenses for new business. The 71,883 million in adjustments to segment assets includes corporate assets of 230,719 million not allocated to reportable segments and a negative 158,836 million elimination of intersegment transactions. Corporate assets are mainly attributed to the Company's surplus management funds (cash and deposits), long-term investment funds (investment securities), deferred tax assets and administrative departments.
 Capital expenditure includes property, plant and equipment, intangible assets and investment property etc.

#### (4) Adjustments from segment income (loss) to income before income taxes

		(Millions of yen)
	FY2019	FY2020
Total reportable segment income	72,330	85,140
Impairment loss	(6,389)	(8,050)
Loss on disposal of non-current assets	(165)	(698)
Loss on related business	(2,287)	(3)
Other	1,080	1,685
Operating income	64,569	78,074
Financial income	5,406	4,297
Financial expense	(9,151)	(8,128)
Income before income taxes	60,824	74,243

#### 10. Information by Region

Sales Revenue		(Millions of yen)		
	FY2019	FY2020		
Japan	667,135	556,023		
China	200,227	226,253		
Asia	158,531	156,133		
America	194,958	154,431		
Europe	107,266	100,072		
Other regions	21,405	18,813		
Total	1,349,522	1,211,725		

 Iteration
 1,043,022
 1,211,123

 Notes:
 1. Sales revenue is classified by country and region based on customer location.

 2. Major countries and regions located in areas outside of Japan and China are as follows:

 (1)
 Asia: Taiwan, South Korea, Thailand, Malaysia, Singapore, India

 (2)
 America: The United States, Mexico

 (3)
 Europe: Germany, France

 (4)
 Other regions: Oceania, Africa